{"DataElement":{"publicId":"3761974","version":"1","preferredName":"Anticoagulant Agent Not Low Molecular Weight Heparin Administered Indicator","preferredDefinition":"Indicator to signify whether or not the patient is receiving anti-coagulants other than low-molecular weight heparin.","longName":"3761951v1.0:3506068v1.0","context":"ABTC","contextVersion":"1","DataElementConcept":{"publicId":"3761951","version":"1","preferredName":"Anticoagulant Agent Not Low Molecular Weight Heparin Administered","preferredDefinition":"Any agent capable of preventing blood clot formation._An operation in which a term denies or inverts the meaning of another term or construction._Substances comprised of fragmented heparin molecules derived from unfractionated heparin that bind to antithrombin III with a molecular weight ranging from 1000 to 10,000 daltons, which causes changes in property from unfractionated heparin, including decreased protein binding, enhanced bioavailability, decreased platelet interaction, and decreased binding to thrombin.(NCI)_The act of having given something (e.g., a medication or test).","longName":"2647695v1.0:3761949v1.0","context":"ABTC","contextVersion":"1","ObjectClass":{"publicId":"2647695","version":"1","preferredName":"Anticoagulant Agent","preferredDefinition":"Agents that prevent blood clotting. Naturally occurring agents in the blood are included only when they are used as drugs.","longName":"C263","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anticoagulant Agent","conceptCode":"C263","definition":"Any agent capable of preventing blood clot formation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"32424AFD-8EFF-572D-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-06-06","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-06-06","modifiedBy":"ONEDATA","dateModified":"2007-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3761949","version":"1","preferredName":"Negation Low Molecular Weight Heparin Administered","preferredDefinition":"An operation in which a term denies or inverts the meaning of another term or construction.:Substances comprised of fragmented heparin molecules derived from unfractionated heparin that bind to antithrombin III with a molecular weight ranging from 1000 to 10,000 daltons, which causes changes in property from unfractionated heparin, including decreased protein binding, enhanced bioavailability, decreased platelet interaction, and decreased binding to thrombin.(NCI):The act of having given something (e.g., a medication or test).","longName":"C25594:C2578:C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Negation","conceptCode":"C25594","definition":"An operation in which a term denies or inverts the meaning of another term or construction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Low Molecular Weight Heparin","conceptCode":"C2578","definition":"Substances comprised of fragmented heparin molecules derived from unfractionated heparin that bind to antithrombin III with a molecular weight ranging from 1000 to 10,000 daltons, which causes changes in property from unfractionated heparin, including decreased protein binding, enhanced bioavailability, decreased platelet interaction, and decreased binding to thrombin.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DCAFF9E9-8DF7-2897-E040-BB89AD4348B0","latestVersionIndicator":"Yes","beginDate":"2013-05-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-05-14","modifiedBy":"ONEDATA","dateModified":"2013-05-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DCAFF9E9-8E08-2897-E040-BB89AD4348B0","latestVersionIndicator":"Yes","beginDate":"2013-05-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-05-14","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":"Created for ABTC eligibility checklist for the 1202 Mk-1775 study per request by J.Zhao. mc 5/14/13 Released per approval by Jason. mc 6/13/13\r\nMoved to ABTC context mc 4/7/14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3506068","version":"1","preferredName":"Yes No Indicator","preferredDefinition":"The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"YES_NO_IND","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"2","maxLength":"3","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"No","valueDescription":"No","ValueMeaning":{"publicId":"3197154","version":"1","preferredName":"No","longName":"3197154","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-55AD-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":"2022.12.28 Alt VM added per ticket request CADSR0001837. aj","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75C2-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"},{"value":"Yes","valueDescription":"Yes","ValueMeaning":{"publicId":"3197153","version":"1","preferredName":"Yes","longName":"3197153v1.00","preferredDefinition":"The affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-558A-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75CC-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"3502157","version":"1","preferredName":"Yes No Indicator Value Domains","preferredDefinition":"Conceptual domain that includes value meanings to be used for Indicator Value Meanings such as Yes, No, Unknown, No Applicable","longName":"YES_NO_IND_VD","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C377DE0C-8C3E-DCA8-E040-BB89AD431B6D","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CURTIST","dateCreated":"2012-06-27","modifiedBy":"CURTIST","dateModified":"2012-06-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2421125","version":"1","preferredName":"Ind-2","preferredDefinition":"A caDSR representation term that is used to indicate a question with permissible values of yes/no","longName":"C38147","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes or No Response","conceptCode":"C38147","definition":"A response or indicator that can have a value of either yes or no.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RETIRED ARCHIVED","registrationStatus":"Retired","id":"0303DF01-F4B4-15EC-E044-0003BA3F9857","latestVersionIndicator":"No","beginDate":"2005-10-18","endDate":"2016-04-27","createdBy":"SHIDED","dateCreated":"2005-10-18","modifiedBy":"TAYLORT","dateModified":"2020-10-03","changeDescription":"10.3.20 TL changed WFS from RETIRED PHASED OUT to RETIRED ARCHIVED. Changed Workflow Status DBW 04-27-2016","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Standard","id":"C37A1BEB-75AE-B6C9-E040-BB89AD434179","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"TSESU","dateModified":"2023-08-16","changeDescription":"8/29/17 tt added CSI per Round 5 finalization task. 3/12/17 jk added Standard reg status; ownership transfered from CTEP to NCI Standards with concurrence of CTEP/Brian Campbell. jk","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3335728","version":"1","longName":"Protocols","context":"ABTC","ClassificationSchemeItems":[{"publicId":"3761917","version":"1","longName":"ABTC 1202","context":"ABTC"}]}],"AlternateNames":[{"name":"CTEP","type":"USED_BY","context":"CTEP"}],"ReferenceDocuments":[{"name":"Is the patient receiving anti","type":"Preferred Question Text","description":"Is the patient receiving anti-coagulants other than low-molecular weight heparin?","url":null,"context":"ABTC"},{"name":"Time Period/Therapy 1","type":"COMMENT","description":"12 weeks - radiation therapy","url":null,"context":"NCIP"},{"name":"Time Period/Therapy 2","type":"COMMENT","description":"6 weeks - nitrosourea chemotherapy","url":null,"context":"NCIP"},{"name":"Time Period/Therapy 3","type":"COMMENT","description":"3 weeks - non-nitrosourea chemotherapy","url":null,"context":"NCIP"},{"name":"Time Period/Therapy 4","type":"COMMENT","description":"4 weeks - any investigational (not FDA-approved) agents","url":null,"context":"NCIP"},{"name":"Time Period/Therapy 5","type":"COMMENT","description":"2 weeks - non-cytoxic, FDA-approved agent","url":null,"context":"NCIP"},{"name":"ABTC-1602 Question","type":"Alternate Question Text","description":"Is the patient taking warfarin, factor Xa inhibitors, and direct thrombin inhibitors? (Low molecular weight heparin and prophylactic low dose warfarin are permitted)","url":null,"context":"ABTC"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DCB1C682-342F-4B3A-E040-BB89AD430E66","latestVersionIndicator":"Yes","beginDate":"2013-05-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-05-14","modifiedBy":"TSESU","dateModified":"2017-09-20","changeDescription":"Created for ABTC eligibility checklist for the 1202 Mk-1775 study per request by J.Zhao. mc 5/14/13 Released per approval by Jason. mc 6/13/13 Moved to ABTC Context mc 4/8/14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}